The University of Southampton
University of Southampton Institutional Repository

Peginterferon-?2a and ribavirin combination therapy in chronic hepatitis C. A randomized study of treatment duration and ribavirin dose

Hadziyannis, Stephanos J., Sette, Hoel, JrMorgan, Timothy R., Balan, Vijayan, Diago, Moises, Marcellin, Patrick, Ramadori, Giuliano, Bodenheimer, Henry, JrBernstein, David, Rizzetto, Mario, Zeuzem, Stefan, Pockros, Paul J., Lin, Amy and Ackrill, Andrew M. (2004) Peginterferon-?2a and ribavirin combination therapy in chronic hepatitis C. A randomized study of treatment duration and ribavirin dose Annals of Internal Medicine, 140, (5), pp. 346-355.

Record type: Article


BACKGROUND: Treatment with pegylated interferon (peginterferon) and ribavirin for 48 weeks is more effective than conventional interferon and ribavirin in patients with chronic hepatitis C.
OBJECTIVE: To assess the efficacy and safety of 24 or 48 weeks of treatment with peginterferon-alpha2a plus a low or standard dose of ribavirin.
DESIGN: Randomized, double-blind trial.
SETTING: 99 international centers. PATIENTS: 1311 patients with chronic hepatitis C.
PATIENTS: 1311 patients with chronic hepatitis C.
INTERVENTION: Peginterferon-?2a, 180 ?/wk, for 24 or 48 weeks plus a low-dose (800 mg/d) or standard weight-based dose (1000 or 1200 mg/d) of ribavirin. Measurement: Sustained virologic response: undetectable HCV RNA concentration at the end of treatment and during 12 to 24 weeks of follow-up.
RESULTS: Overall and in patients infected with HCV genotype 1, 48 weeks of treatment was statistically superior to 24 weeks and standard-dose ribavirin was statistically superior to low-dose ribavirin. In patients with HCV genotype 1, absolute differences in sustained virologic response rates between 48 and 24 weeks of treatment were 11.2% (95% CI, 3.6% to 18.9%) and 11.9% (CI, 4.7% to 18.9%), respectively, between standard- and low-dose ribavirin. Sustained virologic response rates for peginterferon-alpha2a and standard-dose ribavirin for 48 weeks were 63% (CI, 59% to 68%) overall and 52% (CI, 46% to 58%) in patients with HCV genotype 1. In patients with HCV genotypes 2 or 3, the sustained virologic response rates in the 4 treatment groups were not statistically significantly different.
CONCLUSION: Treatment with peginterferon-?2a and ribavirin may be individualized by genotype. Patients with HCV genotype 1 require treatment for 48 weeks and a standard dose of ribavirin; those with HCV genotypes 2 or 3 seem to be adequately treated with a low dose of ribavirin for 24 weeks.

Full text not available from this repository.

More information

Published date: 2004


Local EPrints ID: 27083
ISSN: 0003-4819
PURE UUID: 2dc6a041-d076-47eb-ac04-e66c06606e2c

Catalogue record

Date deposited: 26 Apr 2006
Last modified: 17 Jul 2017 16:05

Export record


Author: Stephanos J. Hadziyannis
Author: Hoel Sette
Author: Timothy R. JrMorgan
Author: Vijayan Balan
Author: Moises Diago
Author: Patrick Marcellin
Author: Giuliano Ramadori
Author: Henry Bodenheimer
Author: David JrBernstein
Author: Mario Rizzetto
Author: Stefan Zeuzem
Author: Paul J. Pockros
Author: Amy Lin
Author: Andrew M. Ackrill

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton:

ePrints Soton supports OAI 2.0 with a base URL of

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.